資源描述：
《非小細(xì)胞肺癌吉西他濱聯(lián)合順鉑治療效果觀察(1).doc》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫(kù)。
1、非小細(xì)胞肺癌吉西他濱聯(lián)合順鉗治療效果觀察⑴非小細(xì)胞肺癌吉西他濱聯(lián)合順鉗治療效果觀察摘要：目的：觀察吉西他濱聯(lián)合順鉗治療非小細(xì)胞肺癌(NomsmallCellLungCancer)的臨床效果。方法:將114例NSCLC患者隨機(jī)分為觀察組(N=52)和對(duì)照組(N二52),觀察組給予吉西他濱聯(lián)合順鉗治療方案，對(duì)照組給予多西他賽聯(lián)合順釦治療方案，觀察兩組患者的臨床有效率和不良反應(yīng)的發(fā)生情況。結(jié)果：觀察組總有效率(47.4%)與對(duì)照組總有效率(43.9%)差異無統(tǒng)計(jì)學(xué)意義(P>0.05)；兩組患者血紅蛋白下降(54.4%vs50.
2、8%)、腎功能異常(21.1%vs24.6%)>惡心嘔吐(47.4%vs49.1%)>腹瀉(8.8%vs5.3%)的發(fā)生率之間的差異無統(tǒng)計(jì)學(xué)意義(P>O.O5)；觀察組肌肉酸痛10.5%、白細(xì)胞下降57.9%、肝功能異常15.8%的發(fā)生率均顯著低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義,P<0.05；皮疹43.9%、血小板下降49.1%的發(fā)生率顯著高于對(duì)照組，P<0.05o結(jié)論：吉西他濱聯(lián)合順鉗是治療非小細(xì)胞肺癌的冇效方法，與多西他賽聯(lián)合治療NSCLC的臨床效果相似，且吉西他濱聯(lián)合順鉗治療的患者不良反應(yīng)較輕，臨床上值得推廣
3、。關(guān)鍵詞：非小細(xì)胞肺癌，吉西他濱，順鉗ClinicaleffectobservationOfgemcitabinecombinedwithcisplatinintreatmentofnon?smallcelllungcancerAbstract：Objective:toobservetheclinicalofgemcitabinecombinedwithcisplatinintreatmentofnon-smallcellIungcancer.Methods:114patientswithNSCLCwererandomlydi
4、videdintoobservationgroup(N=52)andthecontrolgroup(N=52).observationgroupwasgivengemcitabinecombinedwithcisplatin,whilethecontrolgroupwasgivendocetaxelcombinedwithcisplatin,thetotaleffectiverateandadversereactionsoftwogroupswereobserved.Results:Thetotaleffectiverateo
5、ftheobservationgroupwas47.4%‘thetotaleffectiverateofthecontrolgroupwas43.9%,therewasnostatisticallysigrdficantdiffereneeoftwogroups(P>0.05),indiciencerateofdecreasedhemoglobin(54.4%vs50.8%),abnormalrenalfunction(21.1%vs24.6%),nauseaandvomiting(47.4%vs49.1%)zdiarr
6、hea(8.8%vs5.3%)oftwogroupshadnostatisticalsigrdficanceP>0.05;incidencerateofmusclesorenessl0.5%zdecreasedwhitebloodcells57.9%abnormalliverfunction15.8%ofobservationgroupweresign訐icantlylowerthanthatofcontrolgroup,P<0.05;incideneerateofrash43.9%,decreasedplatel
7、et49.1%ofobservationgroupweresigrdficantlyhigherthanthatofcontrolgroupP<O.O5.Conclusion:Gemcitabinecombainedwithcisplatinisaneffectivemethodfornon-smallcelllungcancer;andtheclinicaleffectofgemcitabinecombainedwithcisplatinissimilartothatofdocetaxelcombinedwithcis
8、platin,adversereactionofgemcitabinecombinedwithcisplatinislighterthanthatofdocetaxelcombinedwithcisplatin.thus,thismethodisworthyofclinica
